Previous 10 | Next 10 |
The following slide deck was published by Syneos Health, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Syneos Health, Inc. 2022 Q1 - Results - Earnings Call Presentation
Syneos Health (NASDAQ:SYNH) appointed 30-years industry veteran Michelle Keefe as CEO and a board member. He is with the company since 2017. Keefe, currently President, Medical Affairs and Commercial Solutions, succeeds Alistair Macdonald, who will retire after 20 years at...
Syneos Health press release (NASDAQ:SYNH): Q1 Non-GAAP EPS of $1.01 beats by $0.05. Revenue of $1.34B (+10.7% Y/Y) beats by $20M. For FY2022, the company expects revenue of $5.6B to $5.75B vs. consensus of $5.65B; Adjusted Diluted EPS of $4.98 to $5.24 vs. consensus of $5.08. For further de...
Alistair Macdonald to Retire After 20 Years in Variety of Leadership Roles Michael Brooks Named Chief Operating Officer Company Reports First Quarter 2022 Results and Updates Full Year Guidance MORRISVILLE, N.C., April 29, 2022 (GLOBE NEWSWIRE) -- Syneos Health &...
Highlights Revenue for the first quarter of $1,336.3 million increased 10.5% on a reported basis and 11.7% on a constant currency basis year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $1,2...
Syneos Health (NASDAQ:SYNH) is scheduled to announce Q1 earnings results on Friday, April 29th, before market open. The consensus EPS Estimate is $0.96 (+21.5% Y/Y) and the consensus Revenue Estimate is $1.32B (+9.1% Y/Y). Over the last 2 years, SYNH has beaten EPS estimates 100% of the time ...
AB,ABBV,AON,ARCB,AZN,B,OTCQX:BASFY,BBVA,BCPC,BLMN,BMY,CBOE,CHTR,CL,COWN,CRI,CVEO,CVX,OTCPK:DNNGY,GTLS,HE,HON,IMO,LHX,LNTH,LYB,MGA,NMRK,NVT,NWG,NWL,PSX,SLCA,SYNH,SYNH,TAL,TRP,WETF,WIT,WPC,WY,XOM For Seeking Alpha's full earnings season calendar, click here. For further details see: ...
The shares of the Medpace Holdings (NASDAQ:MEDP) have reached a 52-week low on Tuesday after the contract research organization set the 2022 outlook unchanged despite its 1Q 2022 financials that stood above Street forecasts. The peers in the subsector, including ICON (ICLR), IQVIA Holdin...
The shares of Syneos Health (NASDAQ:SYNH) have recorded the worst intraday performance in over two years to reach a 52-week low after Jefferies downgraded the life sciences company to Hold from Buy citing risks to 2022 guidance. Supporting the thesis, the analysts led by David Windley point o...
Jefferies analyst David Windley downgraded Syneos Health (SYNH -8.0%) to Hold from Buy with a price target of $75, down from $101, making the stock fall 8%. The analyst sees few issues affecting 2022 as, weak 4Q core bookings challenge 2022 Clinical revenue growth with slowing CMD b...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...